• Rita Suhadi Faculty of Pharmacy, Sanata Dharma University, Yogyakarta-Indonesia
  • Jarir At Thobari Faculty of Medicine, Gadjah Mada University
  • Bambang Irawan Faculty of Medicine, Gadjah Mada University
  • Iwan Dwiprahasto Faculty of Medicine, Gadjah Mada University


Objective: To measure the comorbid effect on blood pressure and therapy expenditure in 4 secondary care hospitals in Jogjakarta.

Methods: We conducted an 8-month prospective pharmacoeconomic study with hospital perspective. All hypertensive outpatients, with Askes-insurance whose beneficiaries were governmental employees, with at least 2 moly visits at the index date were included. The subjects with malignancy, hemodialysis, and less than 4 visits were excluded. The expenditure comprised the cost for cardiovascular medicine, doctor, physical/laboratory test, emergency visit, and physiotherapy. We analyzed the expenditure change and sensitivity analysis with Anova-test, whereas the proportion of subjects with good controlled blood pressure with the chi-square test.

Results: The eligible subjects (N=656) consisted of no comorbid (n=105), stroke (n=82), cardiovascular (n=209), diabetes mellitus/chronic kidney disease or DM/CKD (n=149), and combined comorbid (n=111) groups. The baseline blood pressure was similar to no comorbid (p>0.05), except for the diastolic blood pressure in a cardiovascular group. The stroke and cardiovascular groups had more subjects at mean systolic blood pressure lower than 140 mmHg with odds ratio (OR) 2.01 (CI95%:1.12-3.62) and 2.10 (CI95%:1.31-3.39) respectively than no comorbid group; but the mean blood pressure was not clinically different. The total therapy expenditure increased at 6.5% (p<0.61); 22.7% (p<0.03); 78.6% (p<0.01); 78.5% (p<0.01) per subject-visit for stroke, cardiovascular, DM/CKD, and combined-comorbid groups than no comorbid group respectively. Except for stroke group, the incremental expenditure was price-sensitive (p<0.05).

Conclusion: The total therapy expenditure but not blood pressure was likely to be influenced by hypertension comorbidity. We suggest that preventing hypertension comorbidity has the benefit to reduce total therapy expenditure.

Keywords: Hypertension, Comorbidity, Diabetes mellitus, Blood pressure, Stroke, Therapy expenditure


Download data is not yet available.


1. World Heart Federation. Cardiovascular disease risk factors; 2015. Available from: cardiovascular-health/cardiovascular-disease-risk-factors/. [Last accessed on 16 Apr 2015]
2. Mendis S, Puska P, Norrving B. editors. Global atlas on cardiovascular disease prevention and control. Geneva, Switzerland: World Health Organization in collaboration with the World Heart Federation and World Stroke Organization; 2011. Available from: [Last accessed on 12 Dec 2013]
3. World Health Organization (WHO). Cardiovascular Fact Sheet No. 317; 2015. Available from: mediacentre/factsheets/fs317/en/. [Last accessed on 20 Jan 2016]
4. Setiati S, Sutrisna B. Prevalence of hypertension without anti-hypertensive medications and its association with social demographic characteristics among 40 Y and above adult population in Indonesia. Acta Med Indones 2005;37:20-5.
5. Lawes CM, Hoorn SV, Rodgers A. for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-8.
6. Wu Y, Tai ES, Heng D, Tan CE, Low LP, Lee J. Risk factors associated with hypertension awareness, treatment, and control in a multi-ethnic Asian population. J Hypertens 2009;27:190-7.
7. Crawford B, Ong SH, Falvey H. Real-world characterization of hypertension patients in Japan: A 1-Year overview. Asian J Pharm Clin Res 2013;6 Suppl 4:93-6.
8. Turgeon RD, Banh HL, Korownyk C. Is diabetes a coronary artery disease equivalent? Can Fam Physician 2013;69:1306.
9. National Center for Chronic Disease Prevention and Health Promotion. 2014. National Chronic Kidney Disease Fact Sheet; 2014. Available from: pubs/ pdf/kidney_factsheet.pdf. [Last accessed on 20 Jan 2016].
10. McGhan WF. Introduction to Pharmacoeconomics in Pharmacoeconomics from Theory to Practice, Editor Arnold RJG, Boca Raton: CRC Press. e-book; 2010. p. 1-16.
11. Babar ZUD, Scahill S. Is There a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010;28:1069-74.
12. Balu S, Thomas J III. Incremental expenditure of treating hypertension in the United States. Am J Hypertens 2006;19:810-6.
13. Esposti LD, Martino MD, Saragini S. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens 2004;6:76–84.
14. Suhadi R, Yunita L, Dita MV, Setiawan CH. Early implementation of universal health coverage among the hypertension subjects in sleman-district of Yogyakarta. Acta Med Indones 2015;47:311-9.
15. Meraya AM, Raval AD, Sambamoorthi U. Chronic Condition Combinations and Health Care Expenditures and Out-of-Pocket Spending Burden Among Adults, Medical Expenditure Panel Survey, 2009 and 2011. Prev Chronic Dis 2015;12:E12.
16. Trogdon JG, Murphy LB, Khavjou OA, Li R, Maylahn CM, Tangka FK, et al. Costs of chronic diseases at the state level: the chronic disease cost calculator. Prev Chronic Dis 2015;12. http:// 10.5888/pcd12.150131
17. Indonesian Ministry of Health (Kemenkes RI). Riset Kesehatan Dasar; 2013. Available from: upload/article_doc/Hasil_Riskesdas_2013.pdf [Last accessed 20 Jan 2016]
18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M. ESH/ESC Guidelines for the management of arterial hypertension TheT ask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
19. Robertson TA, Cooke CE, Wang J, Shaya FT, Lee HY. Effect of medication burden on the persistent use of lipid-lowering drugs among patients with hypertension. Am J Manag Care 2008;14:710-6.
20. Riewpaiboon A, Pornlertwadee P, Pongsawat K. Diabetes cost model of a hospital in Thailand. Value Health 2007;10:223-30.
21. Doumas M, Papademetriou V, Faselis C, Kokkinos P. Gender differences in hypertension:myths and reality. Curr Hypertens Rep 2013;15:321-30.
22. Ho PM, Bryson CL, Rumsfeld JS. Key issues in outcomes research medication adherence its importance in cardiovascular outcomes. Circulation 2009;119:3028-35.
23. Abidi A, Rizvi DA, Ahmad A. Pharmacoeconomic and drug utilization study of antidiabetic therapy in a tertiary care teaching hospital of Northern India. Asian J Pharm Clin Res 2016;9:371-5.
24. World Health Organization, How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators-EDM Research Series No.007. Available from: medicinedocs/en/d/Js2289e/3.1.html. [Last accessed on 08 Sep 2016]
25. Yoon J, Ettner SL. Cost-sharing and adherence to antihypertensives for low and high adherers. Am J Manag Care 2009;15:833-40.
26. Turki AK, Sulaiman SAS. Elevated blood pressure among patients with hypertension in general hospital of penang, malaysia: does poor adherence matter? Int J Pharm Pharm Sci 2010;2:24-32.
27. McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ. Use of health services by previously uninsured medicare beneficiaries. N Engl J Med 2007;357:143-53.
28. Friedrich EB, Böhm M. Management of end stage heart failure. Heart 2007;93:626-31.
332 Views | 587 Downloads
How to Cite
Suhadi, R., J. A. Thobari, B. Irawan, and I. Dwiprahasto. “THE BLOOD PRESSURE AND THERAPY EXPENDITURE CHANGE DUE TO HYPERTENSION COMORBIDITY: AN ANALYTICAL PROSPECTIVE STUDY IN SECONDARY CARE HOSPITALS IN JOGJAKARTA INDONESIA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 12, Dec. 2016, pp. 78-83, doi:10.22159/ijpps.2016v8i12.14646.
Original Article(s)